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Iron is an essential metal that fine-tunes the innate
immune response by regulating macrophage func-
tion, but an integrative view of transcriptional and
metabolic responses to iron perturbation in macro-
phages is lacking. Here, we induced acute iron chela-
tion in primary human macrophages and measured
their transcriptional and metabolic responses. Acute
iron deprivation causes an anti-proliferative Warburg
transcriptome, characterized by an ATF4-dependent
signature. Iron-deprived human macrophages show
an inhibition of oxidative phosphorylation and a
concomitant increase in glycolysis, a large increase
in glucose-derived citrate pools associated with lipid
droplet accumulation, andmodest levels of itaconate
production. LPS polarization increases the itacona-
te:succinate ratio and decreases pro-inflammatory
cytokine production. In rats, acute iron deprivation
reduces the severity of macrophage-dependent
crescentic glomerulonephritis by limiting glomerular
cell proliferation and inducing lipid accumulation in
the renal cortex. These results suggest that acute
iron deprivation has in vivo protective effects medi-
ated by an anti-inflammatory immunometabolic
switch in macrophages.INTRODUCTION
Iron, an essential metal for life, is a crucial regulator of innate
immunity through macrophage function. Considering its vast
pleiotropic roles in cellular homeostasis and its preferential
enrichment in proteins belonging to mitochondria and the endo-
plasmic reticulum (ER; Andreini et al., 2018), iron has a master
regulatory role in macrophage metabolism and its crosstalk
with immune plasticity. Iron-dependent immunometabolism in
macrophages occurs at multiple levels. Iron could be integrated498 Cell Reports 28, 498–511, July 9, 2019 ª 2019 The Author(s).
This is an open access article under the CC BY license (http://creativeinto heme or iron-sulfur (Fe-S) clusters, which in turn are incorpo-
rated into specific protein families (hemoproteins and Fe-S
cluster proteins) that orchestrate metabolic and immunological
functions in macrophages (Aerbajinai et al., 2019; Drapier and
Hibbs, 1988; Soares and Hamza, 2016; Tong et al., 2018).
Furthermore, in its non-heme, Fe2+ form, iron can govern the
activity of enzymes such as a-ketoglutarate (aKG)-dependent di-
oxygenases upstream of oxygen sensing and epigenetic modifi-
cations (Loenarz and Schofield, 2008; Nakazawa et al., 2016) or
lipoxygenases responsible for generating bioactive lipid media-
tors (Haeggstro¨m and Funk, 2011). Besides its role in promoting
immune activation in macrophages, iron is crucial in regulating
the fundamental properties of eukaryotic cells such as DNA repli-
cation (Netz et al., 2011) and repair (Rudolf et al., 2006), and there
is evidence of macrophage iron levels affecting the proliferation
of stromal cells (Recalcati et al., 2019).
Macrophages show a sophisticated fine-tuning of intracellular
iron availability during bacterial and fungal pathogenicity, a
concept recently referred to as innate nutritional immunity (An-
drianaki et al., 2018; Nairz et al., 2010; Nu´n˜ez et al., 2018). Iron
homeostasis affecting macrophage plasticity was also studied
in the context of sterile inflammation and cancer. It has been re-
ported that iron overloading in macrophages occurs in human
chronic venous leg ulcers and cause an unrestrained pro-inflam-
matory M1-like phenotype (Sindrilaru et al., 2011). Likewise,
increased intracellular iron polarizes the macrophages toward
a detrimental pro-inflammatory state in the injured spinal cord
(Kroner et al., 2014), and iron-positive microglia and macro-
phages in chronic active multiple sclerosis lesions are thought
to be a source of inflammation that correlates with tissue dam-
age and disease severity (Gillen et al., 2018). In keeping with
these findings, in a mouse model of sickle disease, hemolysis
and macrophage heme-iron accumulation trigger a proinflam-
matory phenoytpe in hepatic macrophages (Vinchi et al., 2016).
In cancer, iron-loaded tumor-associated macrophages adopt a
pro-inflammatory phenotype that can directly kill tumor cells
(Costa da Silva et al., 2017), and the usage of iron oxide nanopar-
ticles is an attractive avenue in cancer immunotherapy through
the modulation of macrophage activity (Gu et al., 2019; Zanga-
neh et al., 2016). In summary, the findings from all of thecommons.org/licenses/by/4.0/).
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Figure 1. Acute Iron Deprivation Causes an Atypical Warburg Transcriptome and Mediates an ATF4-Driven Transcriptional Response in
Human Macrophages
(A) Gene set enrichment analysis (GSEA) in upregulated and downregulated transcripts between control (basal) and DEF-treated human macrophages (500 mM,
24 h), measured by RNA-seq (n = 3 donors; Fc > 1.5; Padj < 0.01).
(legend continued on next page)
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above-mentioned studies converge toward a macrophage
polarization profile resulting from prolonged exposure to iron in
the tissue microenvironment, correlating with a pro-inflamma-
tory (M1-like) phenotype. Although this phenotype associates
with tissue damage during inflammatory disease (Kroner et al.,
2014; Sindrilaru et al., 2011; Vinchi et al., 2016), it has been
reported to be beneficial in cancer (Costa da Silva et al., 2017;
Zanganeh et al., 2016).
Studies aiming to experimentally induce acute changes in
cellular iron metabolism during inflammation are scarce.
Reducing mitochondrial iron in the heart protects mice against
ischemia-reperfusion injury (Chang et al., 2016). In human cell
lines, acute iron deprivation results in profound mitochondria-
driven metabolic changes, such as marked citrate accumulation
followed by lipid synthesis and decreases the protein levels of
several Fe-S cluster biogenesis proteins (Crooks et al., 2018;
Tong et al., 2018). These studies suggest that acute manipula-
tion of macrophage iron pools could reprogram its metabolism
in the inflammatory microenvironment. However, a comprehen-
sive study on the effects of iron manipulation in macrophage
metabolism is lacking. Here, we induced acute iron chelation
in primary human macrophages and measured their meta-
bolic and transcriptional responses by stable isotope tracing
and RNA sequencing (RNA-seq). We show that iron deficiency
triggers hypoxia-inducible factor (HIF-1)-glycolysis and inter-
feron (IFN) transcriptional responses, while there is a
generalized downregulation of cell cycle-mitosis and oxidative
phosphorylation (OXPHOS) pathways. We identify ATF4 as an
iron-responsive transcription factor in human macrophages
and show iron-dependent modulation of the expression of
some of its known targets. Thesemajor responses were rescued
with short exposure to FeCl3 following iron chelation. Metaboli-
cally, glucose-derived citrate accumulates markedly and in-
duces intracellular lipid droplet formation, and to a lesser extent
itaconate synthesis, when macrophages lack iron. This is asso-
ciated with the inhibition of the tricarboxylic acid (TCA) cycle,
partly due to the downregulation of succinate dehydrogenase
complex iron sulfur subunit B (SDHB) and the loss of mitochon-
drial aconitase activity. Consequently, OXPHOS is abolished
and glycolysis is enhanced as a result of iron deprivation in
human macrophages. Lipopolysaccharide (LPS) polarization of
iron-deprived human macrophages shows that while the itaco-
nate:succinate ratio is increased, the pro-inflammatory cyto-
kines interleukin-1b (IL-1b) and tumor necrosis factor a (TNF-a)
are reduced. This suggests that iron chelation restrains LPS po-
larization, which is further supported by RNA-seq analysis
showing the induction of the transforming growth factor b
(TGF-b) pathway in LPS-stimulated iron-deprived macrophages.
In vivo, acute iron deprivation reduces the severity of macro-(B) Volcano plot from RNA-seq highlighting genes belonging to glycolysis-HIF, c
(C) qRT-PCR for main glycolysis-HIF, cell division, and OXPHOS genes (color-cod
short exposure (8 h) to 200 mM ferric chloride (DEF + FeCl3); n = 4–9 donors/grou
(D) ATF4 western blotting in iron-deprived (DEF) and rescued (DEF + FeCl3) hum
(E) ATF4 western blotting before and after 2 h of intravenous iron transfusion (Fer
patient information). *p < 0.05, **p < 0.01, and ***p < 0.001 by ANOVA followed by T
bars represent SEM.
See also Figures S1 and S2.
500 Cell Reports 28, 498–511, July 9, 2019phage-dependent crescentic glomerulonephritis by limiting
glomerular cell proliferation and induces significant lipid droplet
accumulation in the renal cortex.
Our study shows that acute iron deprivation results in a pro-
found metabolic remodeling, promoting an atypical Warburg
effect with anti-inflammatory properties in humanmacrophages.
We confirm the beneficial effects of iron deprivation in vivo and
propose macrophage iron manipulation as a potential therapeu-
tic approach targeting immunometabolism in these cells.
RESULTS
Acute Iron Chelation Causes an Atypical Warburg
Transcriptome in Human Macrophages
In mitochondria, the TCA cycle activity, respiration complexes,
and heme biosynthesis are dependent on iron availability and
Fe-S cluster biogenesis. Iron chelators with low membrane
permeability such as deferoxamine cannot access themitochon-
dria, whereas deferiprone (DEF; 3-hydroxy-1,2-dimethylpyridin-
4-one) is membrane permeable and can enter mitochondria
(Sohn et al., 2008). RNA-seq of human macrophages treated
with DEF showed a clear transcriptional response. As previously
shown for iron chelation by chemical hypoxia mimetics (An et al.,
1998; Peyssonnaux et al., 2007), we confirmed a glycolysis-
HIF-P53 signature among the significantly upregulated gene
families (Figures 1A and S1). These cells also show an induction
of IFN signaling, while cell division-mitosis and OXPHOS were
downregulated (Figure 1A). Given the previously established
role of iron chelation in pseudohypoxia (Peyssonnaux et al.,
2007) and cell division-mitosis (Le and Richardson, 2002), these
results suggested iron-dependent transcriptomic changes in
human macrophages. To further confirm that the transcriptional
effects were due to the iron-chelation properties of DEF, human
macrophages were treated with DEF, after which FeCl3 was
added for 8 h. qRT-PCR for themost significant genes belonging
to glycolysis-HIF, OXPHOS, and cell division-mitosis showed
significant rescue of the DEF effect with iron supplementation
in some of the transcripts (Figures 1B and 1C). These results
suggested that the major transcriptomics changes obtained
with DEF treatment are due to iron deprivation in human macro-
phages. Since the results show that acute iron deprivation
is associated with metabolic changes, we next examined
how DEF compares to the well-established lipopolysaccha-
ride (LPS)-mediated transcriptome characterized by increased
glycolysis and attenuated OXPHOS in macrophages (Kelly and
O’Neill, 2015; Mills et al., 2016). Comparative RNA-seq analysis
between LPS and DEF-treated human macrophages showed
that iron deprivation downregulated activating transcription fac-
tor 4 (ATF4)-mediated gene activation (Figure S1). This was notell division, and OXPHOS pathways.
ed) in iron-deprived (DEF, 500 mM, 24 h) and rescued humanmacrophages with
p.
an macrophages from three donors.
inject 1–1.5 g) in 3 CKD patients’ PBMCs (see Method Details and Table S1 for
ukey’s multiple comparisons test. Padj, adjusted p value; Fc, fold change. Error
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Figure 2. Acute Iron Deprivation Abolishes Oxidative Phosphorylation and Increases Aerobic Glycolytic Flux in Human Macrophages
(A) SDHB western blotting in iron-deprived (DEF) and rescued (DEF + FeCl3) human macrophages from three donors. DEF (24 h, 500 mM); FeCl3 (8 h, 200 mM).
(B) Aconitase activity gel in iron-deprived (DEF) and rescued (DEF + FeCl3) human macrophages from two donors. m-aconitase, mitochondrial; c-aconitase,
cytosolic.
(C) Oxygen consumption rate (OCR) measurement by extracellular flux analysis in control and DEF-treated human macrophages. Basal and maximal respiration
and ATP production are shown at right. R/A, rotenone/antimycin; 2-DG, 2-deoxyglucose; DEF (24 h, 500 mM); n = 4 donors.
(legend continued on next page)
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present in LPS-treated cells, which showed the upregulation of
well-established Toll-like receptor, Janus kinase/signal trans-
ducer and activator of transcription (JAK/STAT), and nucleo-
tide-binding oligomerization domain-like (NOD-like) receptor
signaling pathways (Figure S1). We subsequently confirmed
that ATF4 protein levels and the expression of some of its known
target genes are dependent on acute changes in iron (Figures 1D
and S1). To confirm the role of ATF4 in a more clinical setting, we
examined the acute effects of intravenous iron administration
in patients with stable, non-immune chronic kidney disease
(CKD), who were receiving iron therapy as part of their routine
clinical care. Peripheral blood mononuclear cells (PBMCs)
were collected before and 120 min following intravenous iron
(Ferinject 1–1.5 g) infusion, and ATF4 protein levels showed a
clear increase following iron transfusion in all of the patients (Fig-
ure 1E), confirming its iron-mediated rapid induction.
Since metabolic consequences of acute iron deprivation and
defective Fe-S cluster assembly are similar in human cell lines
(Crooks et al., 2018), we next tested an alternative, drug-free
method of acute iron deprivation and replenishment in human
macrophages. RNA interference for ISCU, a primary Fe-S
biogenesis scaffold protein known to have a master regulatory
role in cellular iron levels, showed comparable transcriptomic re-
sponses to DEF (upregulation of glycolysis-HIF-IFN and downre-
gulation of cell-cycle pathways) and the addition of FeCl3
rescued the majority of the effects (Figure S2). Likewise, ISCU
knockdown resulted in ATF4 downregulation, which was
rescued with the addition of FeCl3 in human macrophages
(Figure S2).
Acute Iron Chelation Causes a Metabolic Switch in
Human Macrophages
Iron deprivation resulted in increased glycolysis-HIF, decreased
OXPHOS transcriptome pathways in human macrophages (Fig-
ure 1), indicative of a dysregulation of mitochondrial function.
This was further supported by the suppression of the gene
expression of respiratory chain enzymes containing Fe-S clus-
ters, NDUFS6 and SDHB (also known as the Fe-S subunit of
complex II; Figure 1C). Since SDHB links the TCA cycle to
OXPHOS (Murphy and O’Neill, 2018), we next investigated the
iron-dependent control of its protein levels. SDHB protein levels
were found to be controlled by intracellular iron levels, as iron
replenishment following deprivation brought the levels of this
protein back to its basal state (Figure 2A). As expected, iron-
dependent mitochondrial aconitase activity was inhibited by
DEF (Figure 2B). Iron replenishment partly restored mitochon-
drial aconitase activity and induced cytoplasmic aconitase activ-
ity in human macrophages (Figure 2B). In agreement with SDHB
downregulation and loss of aconitase activity, OXPHOS was
nearly totally inhibited following iron deprivation in human mac-(D) Intracellular and extracellular lactate (glucose-derived adduct shown at left) is
rescued human macrophages with short exposure to 200 mM ferric chloride (DEF
(E) Extracellular glucose M+6 by LC-MS; n = 6 donors.
(F) Extracellular acidification rate (ECAR) measured by extracellular flux analysis
donors.
Significance tested by t test (C, D, and F) and ANOVA followed by Dunnett’s mul
***p < 0.001. Error bars represent SEM.
502 Cell Reports 28, 498–511, July 9, 2019rophages (Figure 2C). To measure the glycolytic rate, we incu-
bated cells with uniformly labeled [U]-13C-glucose and
assessed the production of glucose-derived lactate using liquid
chromatography-mass spectrometry (LC-MS). In line with
the transcriptional changes, we found a significant increase in
the secreted glucose-derived lactate (M+3) with no change in
the consumption of glucose levels following DEF treatment (Fig-
ures 2D and 2E). Consistently, extracellular acidification rate
(ECAR) was enhanced in DEF-treated humanmacrophages (Fig-
ure 2F). These results functionally validated the transcriptional
analyses and confirmed that DEF elicits a metabolic switch
whereby glycolysis is enhanced and mitochondrial function is
suppressed.
A Citrate Checkpoint Characterizes Acute Iron
Deprivation in Human Macrophages
To gain more insights into metabolic pathways affected by acute
iron deprivation and replenishment, we incubated untreated,
iron-deprived, and iron-repleted human macrophages with the
tracer [U]-13C-glucose and assessed its fate in the TCA cycle
(Figure 3A). Iron deprivation and replenishment was well toler-
ated in human macrophages (Figure S3). We observed a striking
increase in citrate levels upon DEF treatment (Figure 3B). The
isotopologue distribution analysis (Figure 3A) revealed that the
increased intracellular citrate pools were predominantly glucose
derived (Figures 3B and S3). Glucose-derived citrate was partly
converted to aconitate and itaconate (Figures 3A, 3B, and S3),
but in relatively modest quantities, which is consistent with the
inhibition of the iron-dependent mitochondrial aconitase activity
(Figure 2B). Metabolites derived from the TCA cycle activity,
such as M+2 glutamate and glutathione (GSH), were decreased,
whileM+2malate remained unchanged (Figures S3 and S4). This
was also the case for the extracellular glutamate, reflected by a
reduction in M+2 glutamate (Figure S4). These results suggested
an inhibition of the TCA cycle between aconitate and aKG.
Furthermore, since nitric oxide synthases (NOSs) are heme-
dependent enzymes responsible for nitric oxide generation
from the oxidation of L-arginine to citrulline (Nathan and Xie,
1994), iron chelation showed an effect on cellular and extracel-
lular arginine and citrulline pools in human macrophages
(Figure S4).
Citrate is an important checkpoint metabolite in immunome-
tabolism, critically positioned at the crosstalk between glucose
catabolism, fatty acid synthesis, and oxidation (Tong and
Rouault, 2007; Williams and O’Neill, 2018). We next hypothe-
sized that marked citrate accumulation following acute iron
deprivation could result in lipid droplet accumulation. In line
with this hypothesis, DEF-treated human macrophages ex-
hibited a striking increase in lipid droplet accumulation, which
was diminished by co-incubation of DEF with FeCl3 (Figure 3C).otopologue quantification by LC-MS in iron-deprived (DEF, 500 mM, 24 h) and
+ FeCl3); n = 6 donors.
. R/A, rotenone/antimycin; 2-DG, 2-deoxyglucose, DEF (24 h, 500 mM); n = 4
tiple comparisons test (E). ns, non-significant compared to Ctrl. **p < 0.01 and
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(A) Diagram of uniformly labeled [U]-13C-glucose catabolism, highlighting the TCA cycle metabolites and their expected glucose-derived 13C atoms.
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Scale bars, 40 mm.
See also Figures S3 and S4.Lipid accumulation was similarly reduced when the fatty acid
synthase (FASN) inhibitor cerulenin was used together with
DEF treatment (Figure S4), suggesting that de novo synthesis
is engaged in iron-depleted macrophages.
In summary, the metabolic reprogramming due to iron depri-
vation results in marked citrate accumulation, which partly trans-
lates into aconitate and itaconate production together with lipid
droplet accumulation (Figure 3D). Oxidative phosphorylation is
inhibited and aKG-derived metabolites show a decrease, sug-
gesting overall diminished activity of the TCA cycle. This causes
a compensatory increase in aerobic glycolysis with the subse-
quent production and secretion of lactate (Figure 3D).
Acute Iron Deprivation and Pro-inflammatory
Macrophage Polarization
To find out how this specific iron-deficient macrophage pheno-
type undergoes the classical pro-inflammatory activation, we
polarizedDEF-treated humanmacrophageswith LPS stimulation
andmeasured IL-1b and TNF-aproduction. The results showed a
reduction in secreted factors in iron-chelated macrophages (Fig-
ure 4A). We then performed a time course analysis of LPS treat-
ment in DEF-treatedmacrophages andmeasured 88metabolites
by LC-MS, including citrate, aconitate, itaconate, and succinate
(Figure 5). We first confirmed the truncated TCA cycle in LPS-stimulated iron-deprived macrophages with increased citrate
(and citrate:succinate ratio) and aconitate and decreased aKG
and glutamate levels (Figures 4B, 4C, and S5). Itaconate produc-
tion is further augmented in DEF-treated human macrophages,
and the itaconate:succinate ratio was increased at 24 h (Figures
4B and 4C), which is indicative of overall anti-inflammatory meta-
bolic switching (Murphy and O’Neill, 2018). IRG1 mRNA levels
did not show an apparent DEF effect, suggesting that the effects
of iron deprivation on itaconate levels are likely to bemediated by
changes in metabolic fluxes, rather than by the transcriptional
regulation of IRG1 (Figure S5). Comparative RNA-seq analysis
between LPS and LPS + DEF-treated macrophages during early
activation (3 h) confirmed the results obtained with Ctrl versus
DEF comparison (i.e., increased glycolysis, IFN-g signaling,
decreased OXPHOS, and DNA replication; Figure S5). Iron-
depleted macrophages stimulated with LPS showed upregula-
tion of the TGF-b signaling pathway, which is associated with
increases in TGFB1, VEGFA, CTGF, CXCL12, IL10, and IL1RN
expression levels (Figure S5). Considering the anti-inflammatory
role of itaconate (Bambouskova et al., 2018; Mills et al., 2018),
these results suggest that acute iron chelation limits the classical
macrophage polarization by increasing the itaconate:succinate
ratio, decreasing secreted IL-1b, and TNF-a, and promoting the
early induction of the TGF-b signaling pathway.Cell Reports 28, 498–511, July 9, 2019 503
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See also Figure S5.Acute Iron Deprivation Is Preventive in
Glomerulonephritis and Induces De Novo Lipogenesis
To investigate the pathophysiological significance of acute iron
deprivation in a macrophage-dependent inflammatory disease
model, crescentic glomerulonephritis was induced in the Wistar
Kyoto rats treated either with vehicle or DEF (Figure 6A). Oral
DEF treatment markedly lowered the levels of proteinuria during
the entire disease course (Figure 6B) and ameliorated glomerular
morphology (Figure 6C). The glomeruli of the DEF-treated group
had a substantially reduced fibrin score and crescent formation
as well as decreased glomerular size (Figure 6D). Since the WKY
nephrotoxic nephritis (NTN) model depends on the infiltration
and activation of monocytes and macrophages (Behmoaras
et al., 2010), we performed ED-1 (rat CD68) staining and showed
that DEF significantly decreased the number of monocytes and504 Cell Reports 28, 498–511, July 9, 2019macrophages in the glomeruli (Figure S6). We then checked
whether the lipid accumulation as a result of iron deprivation
was conserved in vivo and found increased oil red O staining in
DEF-treated rat glomeruli and renal cortex following NTN (Fig-
ure 6E), suggesting that the citrate-derived de novo fatty acid
synthesis occurs during acute iron deprivation in experimental
crescentic glomerulonephritis. Furthermore, since iron depriva-
tion caused a downregulation of cell cycle-mitosis pathways
measured by RNA-seq (Figure 1A), wemeasured intraglomerular
cell proliferation and found decreased proliferating glomerular
cell nuclear antigen (PCNA) in DEF-treated animals following
the induction of NTN (Figure 6F).
To assess whether DEF has therapeutic effects after the onset
of glomerulonephritis, rats were treated with or without DEF from
day 4 following the induction of NTN, which corresponds to the
Ctrl 1h 3h 8h 24h 
LPS LPS+DEF 
1h 3h 8h 24h 
Figure 5. Acute Iron Chelation and Time Course Metabolomics in LPS-Stimulated Human Macrophages
Heatmap for LC-MS analysis of 88 metabolites in basal (Ctrl), LPS treated (1, 3, 8, and 24 h) and LPS + DEF-treated human macrophages; DEF treatment is
500 mM, 24 h; n = 4 donors.onset of renal damage and proteinuria. The rats were then sacri-
ficed on day 10, at the peak of glomerular inflammation (Fig-
ure 6G). Notably, the progression of proteinuria at day 10 was
reversed in rats treated with DEF when compared to either the
treated group on day 7 or their control counterparts at day 10
(Figure 6H). The glomerular morphology of DEF-treated rats at
day 10 showed improved features when compared to vehicle-
treated rats (Figure 6I), which was also accompanied by reduced
fibrin score and crescent formation together with decreased
glomerular size (Figure 6J). Monocyte/macrophage infiltration
was significantly decreased by DEF (Figure S6), and acute iron
deprivation by DEF resulted in ameliorated renal function (i.e.,reduced creatinine and blood urea nitrogen) associated with
reduced intraglomerular cell proliferation (Figure S6). DEF treat-
ment did not alter erythropoiesis as hemoglobin levels were
not significantly altered (Figure S6). In addition to its therapeutic
effects in vivo, DEF reduced superoxide production in the NTN-
susceptible WKY rat bone marrow-derived macrophages
(BMDMs) and its antioxidant properties were confirmed in a
cell-free superoxide production system (Figure S6). In summary,
in vivo iron chelation in macrophage-dependent renal inflamma-
tion is accompanied by metabolic and transcriptomic changes
(de novo lipid accumulation, anti-proliferative responses) that
are conserved in vitro cultured human macrophages.Cell Reports 28, 498–511, July 9, 2019 505
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Figure 6. Acute Iron Deprivation Protects against Crescentic Glomerulonephritis and Induces De Novo Lipid Accumulation
(A) Experimental design.
(B) Amount of urinary protein at different time points during the course of NTN; n=3 or 4 rats/group.
(C) PAS staining showing representative glomerular morphology of the vehicle (left) and the DEF (right) groups.
(D) Glomerular fibrin score, percentage of glomeruli with crescents, and glomerular size in vehicle and DEF-treated rats; n = 3 or 4 rats/group.
(E) Nephritic glomeruli of vehicle- or DEF-treated rats showing oil red O+ glomerular and tubular cells in the DEF group.
(F) PCNA staining showing proliferating cells in nephritic glomeruli; number of nuclear PCNA(+) cells in the glomeruli (bottom); n = 3 or 4 rats/group.
(G) Experimental design for the therapeutic experiment.
(legend continued on next page)
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DISCUSSION
Iron serves as a prosthetic group for proteins orchestrating im-
munometabolic responses at multiple levels in macrophages.
For instance, mammalian complex I hosts as many as eight
Fe-S clusters (Vinothkumar et al., 2014), allowing optimal elec-
tron transfer during OXPHOS and maintaining the balance
between the generation of reactive oxygen species (ROS) and
ATP production (Mills et al., 2016). Furthermore, non-mitochon-
drial ROS production, an essential feature of macrophage-driven
immune phagocytic responses, is partly mediated by NOX2
(CYBB), which uses heme-iron for superoxide generation (Sumi-
moto, 2008). In this study, we showed that iron deprivation
caused an induction of glycolysis-HIF and a repression of
OXPHOS pathways in human macrophages. Dendritic cells
andmacrophages, when stimulated with pro-inflammatory stim-
uli, decrease OXPHOS with a simultaneous upregulation of
glycolysis and activity in the pentose phosphate pathway
(Krawczyk et al., 2010; Mills et al., 2016; Tannahill et al., 2013).
Although iron deprivation and pro-inflammatory M1-type macro-
phage stimulation share the samemetabolic switch, the underly-
ing mechanisms are likely to differ. The inhibition of OXPHOS is
explained by nitric oxide-mediated nitrosylation of mitochondrial
Fe-S clusters in LPS-stimulated murine macrophages (Drapier
and Hibbs, 1988; Everts et al., 2012). Instead, iron deprivation
directly affects the expression and protein levels of respiratory
chain Fe-S enzymes such as NDUFS6 and SDHB. It causes
the loss of OXPHOS and ATP production, partly by reducing
SDHB levels in conjunction with the inhibition of mitochondrial
aconitase activity. The rapid increase in SDHB levels following
iron replenishment suggests the existence of an iron-responsive
element in SDHB mRNA, which was previously reported in
Drosophila (Kohler et al., 1995). Furthermore, SDHB deletion
was associated with reduced IL-1b and HIF-1a in LPS-stimu-
lated macrophages (Mills et al., 2016), although LPS stimulation
itself was shown to diminish SDHB protein levels in RAW264.7
cells (Tong et al., 2018). Considering the large-scale suppression
of Fe-S cluster biogenesis proteins in response to TLR4 activa-
tion in murine cell lines (Tong et al., 2018) and the previously
described iron-sequestration phenotype in M1 human macro-
phages (Recalcati et al., 2010), one could speculate that
mitochondrial iron deprivation, M1 activation, and ISCU small
interfering RNA (siRNA) or mutagenesis share in the common in-
hibition of OXPHOS and a concomitant increase in aerobic
glycolysis in macrophages.
DEF is an orally active Food and Drug Administration (FDA)-
approved iron chelator that preferentially binds to ferric iron
(Fe3+) in a 3:1 configuration and is used as alternative or comple-
mentary to deferoxamine treatment in hemoglobinopathies char-
acterized by iron overload (Hider and Hoffbrand, 2018). DEF can
enter the mitochondria and shuttle iron between subcellular
compartments (Sohn et al., 2008). Because of its low affinity to(H) Amount of urinary protein levels at different time points during the course of
(I) PAS staining showing representative glomerular morphology of the vehicle (le
(J) Glomerular fibrin score, percentage of glomeruli with crescents, and glomeru
*p < 0.05, **p < 0.01, and ***p < 0.001 by t test. Scale bars, 40 mm. Error bars re
See also Figure S6.iron, DEF is less likely to cause iron depletion, which we also
confirmed by measuring DEF-treated mitochondrial and cyto-
solic iron in human macrophages (data not shown). The ability
of DEF to chelate mitochondrial iron and to make it available
for other cellular compartments (Kakhlon et al., 2008) has thera-
peutic benefit for disorders such as Friedreich ataxia character-
ized by altered mitochondrial Fe-S cluster biogenesis (Pandolfo
and Hausmann, 2013). More generally, mitochondrial iron
handling is central to regulating cellular and systemic homeosta-
sis (Paul et al., 2017). In this context, the distinct properties of
DEF make this drug ideal for studying the metabolic conse-
quences arising from mitochondrial iron imbalances rather than
measuring the indirect effects of extracellular iron chelation
obtained by using deferoxamine. Iron imbalances between
mitochondria and cytosol can have broad pathological conse-
quences in cancer through altered immunometabolism (Li
et al., 2018), and the genetic deficiencies of mitochondria-
related genes (FH, PINK1) are likely to trigger dysregulation of
the mitochondria-cytosol iron balance, which is associated
with the Warburg effect and HIF signature in cancer (Li et al.,
2018; Tong et al., 2011; Tyrakis et al., 2017). We observed a
macrophage pseudohypoxia transcriptome (i.e., HIF response
in the presence of oxygen; Selak et al., 2005; Tannahill et al.,
2013) with DEF treatment, which was previously described in
LPS-stimulated macrophages (Tannahill et al., 2013). One limita-
tion of our study is that the use of FeCl3 for iron replenishment
in vitro does not mimic exposure to heme-iron, which occurs
in vivo through the phagocytosis of red blood cells by macro-
phages due to hemorrhage, as reported in spinal cord injury
(Kroner et al., 2014). In hemolytic diseases, which are character-
ized by the enhanced release of hemoglobin and heme into the
circulation, heme-iron loading of reticulo-endothelial system
macrophages changes their activation (Vinchi et al., 2016).
Nonetheless, macrophages can also be exposed to non-heme
iron released from dying cells, and it should also be noted that
the pro-oxidant properties FeCl3 may exacerbate the oxidative
stress and trigger the ATF4 response.
One major transcriptional response that was specific to DEF
treatment was ATF4 downregulation. Given the induction of
this transcription factor in oxidative and ER stress responses
(Ameri and Harris, 2008) and during heme-dependent erythroid
differentiation (Suragani et al., 2012), this result confirms the anti-
oxidant properties of DEF and its effect on superoxide neutrali-
zation. Furthermore, ATF4 reprograms CD4+ T cell metabolism
and immune response (Yang et al., 2018), and it is therefore
conceivable that it has a similar role in human macrophages,
especially given its effect on glutathione levels (Yang et al.,
2018). Another distinct feature of acute iron deprivation was its
modest itaconate production when compared to LPS-stimulated
human macrophages, which produce large amounts of this anti-
inflammatory metabolite (Mills et al., 2018; Papathanassiu et al.,
2017). The limited itaconate production with iron deprivationNTN; n = 4 or 5 rats/group.
ft) and DEF (right) groups.
lar size in vehicle- and DEF-treated rats; n = 4 or 5 rats/group.
present SEM.
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could come from the type 1 interferon response affecting IRG1
gene expression (Mills et al., 2018). Considering the anti-inflam-
matory (Lampropoulou et al., 2016; Mills et al., 2018) and pro-
tumorigenic (Weiss et al., 2018) effects of itaconate, it may
contribute to the broadly anti-inflammatory macrophage pheno-
type we observe following iron deprivation. LPS stimulation aug-
ments itaconate production in iron-deprived macrophages and
increases the itaconate:succinate ratio, while decreasing IL-1b
and TNF-a secretion and promoting the TGF-b signaling
pathway. These results indicate that acute iron chelation limits
classic LPS polarization partly through the immunomodulatory
properties of itaconate. A recent addition to the latter is the
inhibitory effects of itaconate during immune tolerance (Domi-
nguez-Andres et al., 2019). Furthermore, itaconate is bacteri-
cidal, which is in line with the previously established antibacterial
properties of iron chelators (Thompson et al., 2012).
Acute iron deprivation in human macrophages resulted in a
robust citrate accumulation, which could be primarily attributed
to aconitase inhibition. Mitochondrial and cytosolic aconitases
catalyze the interconversion of citrate and isocitrate, and their
activities are affected by cellular iron and oxidative levels and
the activity of Fe-S biogenesis (Tong and Rouault, 2007). Citrate
can be transported across the inner mitochondrial membrane via
the tricarboxylate carrier, and once in the cytosol, it is the sub-
strate of ATP-citrate lyase, which generates acetyl-coenzyme
A (CoA), the building block of cholesterol and the fatty acids.
De novo fatty acid synthesis is the hallmark of LPS-stimulated
dendritic cells (Everts et al., 2014) and macrophages (Carroll
et al., 2018). Fatty acid oxidation has been associated with
pro-inflammatory macrophage activation (Hall et al., 2013,
2018), which highlights the complexity of lipid metabolism
and the possible master-regulatory role of citrate in fine-
tuning context-dependent macrophage responses. Here, we
found that macrophages accumulate lipid droplets as a result
of iron deprivation. In contrast with what was observed with
TNF/IFN stimulation (Infantino et al., 2014), the marked citrate
accumulation was not associated with a pro-inflammatory
signal, suggesting that citrate pools are preferentially used for
lipogenesis, causing steatosis in macrophages and nephritic
kidneys. Citrate and iron metabolism are intimately linked as cit-
rate can chelate divalent cations such as Fe2+ and is proposed to
be one of the carriers of non-transferrin-bound iron (Grootveld
et al., 1989). It can also inhibit succinate oxidation (Hillar et al.,
1975). Systemically, elevated citrate levels have been linked to
increased hepcidin mRNA expression in primary hepatocytes
and in vivo (da Silva et al., 2017), suggesting the existence of a
citrate-iron regulatory feedback loop in macrophages. Citrate
has also been linked to IFN-g production through the acetylation
of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in
T cells (Balmer et al., 2016), a mechanism that could explain
enhanced IFN response in iron-deprived human macrophages.
Studies on macrophage polarization following the manipula-
tion of intracellular iron levels by different means has resulted
in contrasting results, presumably because of the different
model systems and the possible existence of a critical concen-
tration of intracellular iron that likely drives the polarization (Re-
calcati et al., 2019). While treatment with hepcidin resulted in
the attenuation of the inflammatory response in LPS-treated508 Cell Reports 28, 498–511, July 9, 2019macrophages (De Domenico et al., 2010), dietary iron restriction
rendered spleen macrophages pro-inflammatory following sub-
lethal LPS injection in mice (Pagani et al., 2011). No obvious
changes in BMDMpolarization markers were observed following
the conditional deletion of ferroportin from the myeloid lineage
(Recalcati et al., 2019). More recently, and in accordance
with our findings, the knock down of glia maturation factor-g
(GMFG) in macrophages was shown to cause an iron-deficiency
response and M2 macrophage polarization associated with
reduced mitochondrial respiration chain components, ISCU,
and basal oxygen consumption and an increased HIF response
(Aerbajinai et al., 2019). Likewise, treatment with iron led to M1
polarization in mice BMDMs (Handa et al., 2019).
The acute iron chelation in experimental glomerulonephritis re-
sulted in de novo lipid synthesis but ameliorated the renal
outcome. Considering that defective fatty acid oxidation was
linked to fibrosis in CKD (Kang et al., 2015), these results argue
in favor of a possible transient beneficial role of de novo lipogen-
esis in inflammation, as observed by others (Papazyan et al.,
2016; Solinas et al., 2015). The systemic use of DEF in macro-
phage-dependent inflammatory disease should take into ac-
count the extent of iron loading in macrophages residing in
different tissues. In fact, depending on tissue-dependent varia-
tion in ferroportin levels (Drakesmith et al., 2015), the macro-
phage iron content is likely to differ in different organs, and
systemic iron deprivation may not have the same effect on infil-
trating and tissue-resident macrophages.
When compared with the well-known LPS/Toll-like receptor 4
(TLR4)-induced Warburg effect in macrophages, iron depriva-
tion-mediated immunometabolism could be considered atypical
(i.e., a sterile Warburg effect devoid of pro-inflammatory pro-
gramming), suggesting the different degrees of this phenomenon
in the spectrummodel of macrophage plasticity. In summary, im-
munometabolic changes derived from acute iron deprivation in
macrophages could be considered a future therapeutic angle in
macrophage-dependent inflammatory disease.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Rats
WKY (male, 16-weeks old, WKY/NCrl) rats used for NTN experiments were purchased from Charles River UK. All rats were used
straight from the source by housing them until the appropriate experimental age. All procedures were performed in accordance
to institutional guidelines and procedures approved by the UK Home Office (United Kingdom Animals Scientific Procedures Act,
1986).
CKD patients
Acute effects of intravenous iron administration were investigated in patients with stable non-immune chronic kidney disease, not
requiring renal replacement therapy. Samples were provided after written informed consent, and in accordance with NHS Health
Research authority approval. A summary of patient characteristics is provided in Table S1. All patients were clinically well, without
evidence of acute infection or incurrent illness at the time of iron administration, and none had received intravenous iron or blood
transfusion in the preceding three months.
METHOD DETAILS
Isolation of macrophages and PBMCs
Human monocyte-derived macrophages (hMDMs) were differentiated from buffy cones from healthy donors using gradient separa-
tion (Histopaque 1077, Sigma) and adhesion purification. Following Histopaque separation, peripheral bloodmononuclear cells wereCell Reports 28, 498–511.e1–e5, July 9, 2019 e2
re-suspended in RPMI 1640 (Life Technologies), and monocytes were purified by adherence for 1 hour at 37C, 5%CO2. The mono-
layer was washed three times with HBSS to remove non-adherent cells, and monocytes were matured for 5 days in RPMI containing
100 ng/mL macrophage colony-stimulating factor (M-CSF, PeproTech, London, UK) and 10% fetal calf serum (Labtech Interna-
tional). For the deferiprone (DEF) treatment, macrophages were treatedwith 500 mMDEF (Sigma), in full culturemedia overnight. Cells
were then prepared for either RNA-sequencing or LC-MS experiments using D-Glucose U-13C. For rescue experiments involving the
addition of FeCl3, macrophages deprived from iron with over-night DEF treatment, were treated with FeCl3 (200 mM, Sigma) for
8 hours, after which the cells were isolated and used in different assays. Lipopolysaccharide (LPS, Sigma) treatment of hMDMs
was used either for RNA-seq or LC-MS experiments.
CKD patients received intravenous iron, as Ferinject (ferric carboxymaltose, 50mg/mL) at a total dose of 1-1.5g by slow infusion
over 30 minutes. Peripheral blood was drawn in EDTA immediately prior and 120 min following iron infusion, and processed imme-
diately. Peripheral blood mononuclear cells (PBMCs) were isolated by Histopaque (1077, Sigma) density gradient centrifugation and
used for ATF4 Western Blotting before and after iron infusion.
Metabolic extracellular flux analysis
Real-time measurements of OCR and ECAR were performed using a Seahorse XF96 Extracellular Flux Analyzer (Agilent Technolo-
gies). hMDMs cultured for 5 days in presence of RPMI containing M-CSF (100 ng/ml) and FCS (10%) were washed and incubated
with DEF. Cells were then washed, re-suspended using the non-enzymatic cell dissociation buffer (Sigma) and 5 3 105 hMDMs
were seeded as a monolayer in a 96-well microplate containing Seahorse XF RPMI medium (Agilent Technologies). The different
metabolic drugs were injected (oligomycin 1mM, FCCP 2mM, rotenone/antimycin 1mM, 2-DG 50mM) during real-time measurements
of OCR and ECAR, using the Seahorse XFCell Mito Stress Test Kit (Agilent Technologies). Basal respiration was calculated as the last
measurement before addition of oligomycin – non mitochondrial respiration (minimum rate measurement after Rot/AntA). Maximal
respiration is shown as the maximum rate measurement after addition of FCCP – non mitochondrial respiration. Estimated ATP pro-
duction designates the last measurement before addition of oligomycin – minimum rate after oligomycin. Glycolysis refers to ECAR
values before the addition of oligomycin.
Stable isotope tracing by liquid chromatography-mass spectrometry (LC-MS)
For stable isotope tracing, human macrophages (treated or left as basal) were incubated for 8 hours with SILAC medium lacking
glucose and phenol red (GIBCO) with addition of L-glutamine (0.5 mM), arginine (200 mg/L), lysine (40 mg/L) and uniformly labeled
glucose (2 g/L D-Glucose U-13C, 99%, Cambridge isotope laboratories). Cells were then washed three times with PBS and 200ml of
extraction buffer (50% LC-MS grademethanol and 30% acetonitrile, 20% ultrapure water) was added per 106 cells. Following 15min
incubation in dry ice, the cells were scraped off and kept under vigorous shaking for 15 min at 4C, and left for 1 hour incubation at
20C. Following centrifugation, the supernatant was stored at 80C until further analysis. For the cell supernatant analysis,
the same procedure was performed in supernatant obtained from 106 cells. For the steady-state metabolomics analysis, cells
were stimulated with LPS and DEF or left unstimulated (basal) at indicated times, followed by the same extraction procedure
described above.
Samples were randomized in order to avoid bias due to machine drift and processed blindly. LC-MS analysis was performed using
a Q Exactive mass spectrometer (Thermo Fisher Scientific) coupled to a Dionex U3000 UHPLC system. The liquid chromatography
system was fitted with a Sequant ZIC-pHILIC column (150 mm3 2.1 mm) and guard column (20 mm3 2.1 mm) fromMerck Millipore
(Germany) and temperaturemaintained at 40C. Themobile phasewas composed of 20mMammonium carbonate and 0.1%ammo-
nium hydroxide in water (solvent A), and acetonitrile (solvent B). The flow rate was set at 200 mL/min with the gradient as described
previously (Mackay et al., 2015). The mass spectrometer was operated in full MS and polarity switching mode. The acquired spectra
were analyzed using XCalibur Qual Browser and XCalibur Quan Browser software (Thermo Fisher Scientific). To generate the heat-
map, the raw data were normalized by total ion count and missing values were replaced by half of the minimum value of each metab-
olite. Heatmap was then generated with the heatmap.2 function of the gplots package by creating z-score values and using default
clustering methods.
RNA extraction and library preparation
Total RNA was extracted from hMDMs using Trizol (Invitrogen) and RNeasy mini kit (QIAGEN) according to manufacturer’s instruc-
tions, with an additional purification step by on-column DNase treatment using the RNase-free DNase Kit (QIAGEN) to ensure elim-
ination of any genomic DNA. The integrity and quantity of total RNA was determined using a NanoDrop 1000 spectrophotometer
(Thermo Fisher Scientific) and Agilent 2100 Bioanalyzer (Agilent Technologies). 500 ng of total RNA was used to generate RNA-seq
libraries using NEBNext Ultra II Directional RNA Library Prep kit from Illumina, according to the manufacturer’s instructions. Briefly,
RNA was purified and fragmented with poly-T oligo-attached magnetic beads, using two rounds of purification followed by the first
and second cDNA strand synthesis. Next, cDNA 30 ends were adenylated and adapters ligated followed by 11 cycles of library ampli-
fication. The libraries were size selected using AMPure XP Beads (Beckman Coulter), subsequently purified and their quality was
checked using Agilent 2100 Bioanalyzer. Samples were randomized to avoid batch effects and multiplexed libraries were run on a
single lane (8 samples/lane) of the HiSeq 2500 platform (Illumina) to generate 100bp paired-end reads.e3 Cell Reports 28, 498–511.e1–e5, July 9, 2019
Bioinformatics
An average depth of 52 M reads per sample was achieved. Sequencing adapters were removed using Trimmomatic (v.0.36) and the
reads quality was checked using FastQC (v.0.11.2) before and after trimming. Reads were aligned to the human genome
(GRCh38.primary_assembly.genome.fa; annotation: gencode.v25.annotation.gtf) using tophat2 package (v.2.1.0: -b2-sensitive,–
library-type fr-firststrand). An average mapping percentage of 97.1% was achieved and the average number of properly paired
reads was 51.4 M (95%). Mapping quality, read distribution, gene body coverage, GC content and rRNA contamination, were
checked using picard (v.2.6.0) software. Gene level read counts were computed using HT-Seq-count (v.0.6.1) with strict ‘‘-m inter-
section-strict’’ mode. Genes with less than 10 aligned reads across all samples were filtered out as lowly expressed genes, resulting
in 15,732 expressed genes. Differential gene expression analysis between groupswas performed usingDESeq2 (v.1.14.1) and signif-
icantly differentially expressed genes were reported using a cut-of fold-change (FC) at 1.5 and below 1% Benjamini-Hochberg (BH)
adjusted P-value (Padj). Unsupervised hierarchical clustering and principal component analysis (PCA) were performed using
pcaExplorer (v.2.6.0, https://github.com/federicomarini/pcaExplorer) and pheatmap (v 1.0.10, https://cran.r-project.org/web/
packages/pheatmap/index.html) packages respectively. Volcano plots of differentially expressed genes were generated using
ggplot2 (v.3.0.0, https://cran.r-project.org/web/packages/ggplot2/index.html) package. All raw RNA-seq data processing steps
were performed in Cx1 high-performance cluster computing environment, Imperial College London. Further analyses were conduct-
ed in R/Bioconductor environment v.3.4.4 (http://www.R-project.org/).
Gene Set Enrichment Analysis (GSEA v5.2, http://software.broadinstitute.org/gsea/index.jsp) was utilized to identify potential spe-
cific biological pathway or signature enrichment between different treatment groups. All gene sets with an FDR less than 0.25 were
considered as statistically significant. For gene ontology (GO) analysis, a cut-of (FC > 1.5, Padj < 0.01) was applied to the differentially
expressed genes and the resulting transcripts were entered to STRING database (https://string-db.org/) to interrogate protein-
protein interactions together with pathway enrichement.
Quantitative RT-PCR
Total RNA was extracted from human macrophages using the TRIzol reagent (Invitrogen) according to the manufacturer’s instruc-
tions, and cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad). A total of 10 ng cDNA for each sample was used.
All quantitative RT-PCRs were performed on a ViaA 7 Real-Time PCR System (Life Technologies) using Brilliant II SYBR Green
QPCR Master Mix (Agilent), followed by ViiA 7 RUO Software for the determination of Ct values. Results were analyzed using the
comparative Ct method, and each sample was normalized to the reference mRNA level of HPRT gene, to account for any potential
cDNA loading differences.
Western blotting
Human macrophages were lysed in Laemmli sample buffer supplemented with protease inhibitors and resolved by SDS-PAGE,
transferred into PVDF membranes, and subjected to immunoblotting with the primary antibodies against ATF4 (Cell Signaling
Technologies), SDHB (Abcam), ACTB (Santa Cruz) and secondary detection antibodies. The probed proteins were detected using
SuperSignal West Femto Chemiluminescent Substrate (Thermo Fisher Scientific Inc., Rockford, IL).
RNA interference
hMDMs were re-plated in six-well plates (1 3 106 cells per well) in RPMI (Invitrogen) overnight and transfected with siGENOME
SMARTpool for human ISCU (100 nM, Dharmacon SMART pool) or non-targeting siRNA pool as the scrambled control siRNA using
Dharmafect 1 (1:50, Dharmacon) as a transfection reagent in OPTIMEMmedium (Invitrogen). Following 8 h incubation with OPTIMEM
media containing either ISCU or non-targeting siRNA, cells were washed and further cultured for 48 h in presence of RPMI media
containing M-CSF and FCS. Iron supplementation was achieved by culturing the macrophages for an additional 8 hours in presence
of FeCl3.
ELISA
Detection of human IL-1b and TNFa (Invitrogen) in hMDM culture supernatants at indicated conditions, were performed by sandwich
ELISA, using technical duplicates, following themanufacturer’s recommendations. Light absorbance wasmeasured usingMultiscan
Ascent (Thernofisher).
Nephrotoxic Nephritis and immunohistochemistry
MaleWKY rats (Charles River UK) weighing 300-360 g were used for the induction of nephrotoxic nephritis (NTN). Nephrotoxic serum
was prepared in rabbits and NTN was induced by intravenous injection as previously described (Tam et al., 1999). Groups of animals
were given either DEF (200mg/kg/day in 0.1% carboxymethyl cellulose by oral gavage) or vehicle only. Rats were individually housed
in metabolic cages overnight for urine collection, and urinary protein levels were determined by sulphosalicylic acid method. Serum
blood urea nitrogen and creatinine were measured using an Abbott Architect c8000 clinical chemistry analyzer. Paraffin-embedded
kidneys were sectioned for periodic acid-Schiff (PAS) staining. Fibrin deposition was scored as the number of glomerular quadrants
involved from ‘0’ (absence of fibrin) to ‘4+’ (fibrin occupying more than 3/4 of the glomerulus) in 50 consecutive glomeruli. Crescent
formation was recorded as presence/absence in 100 consecutive glomeruli and presented as percentage of glomeruli withCell Reports 28, 498–511.e1–e5, July 9, 2019 e4
crescents. Immunohistochemistry was performed and developed with EnVision+ System-HRP (Dako) using mouse anti-rat ED1
(Bio-Rad) and anti-PCNA [PC10] (Abcam) antibodies. Pictures of 20 consecutive glomeruli from each ED1 stained slide were taken
with a QImaging Retiga 2000R Scientific CCD Camera, using Image-Pro Plus Version 7.0 software. The size of the glomeruli and
ED1 stained area in glomeruli were measured using ImageJ software. The number of anti-PCNA stained cells in 20 consecutive
glomeruli were counted. All histological and immunohistochemical analyses were performed in a blinded manner.
Oil-red-o staining
Optimal Cutting Temperature compound embedded frozen rat kidneys were sectioned at 5 microns thickness and 10% formalin
fixed for 10 min at room temperature prior to staining. hMDMs cultured in slide-chambers were treated with DEF alone (500 mM)
or together with FeCl3 (200 mM) or cerulenin (20 mM) for 48 hours. The cells were fixed with 10% formalin at 4
C. Kidney sections
and hMDMs were stained for lipids by Oil-Red-O (0.5% Oil red O dye in 60% isopropanol; Sigma) and counterstained with Haema-
toxylin (Sigma). Pictures were obtained by light microscopy using a Leica DM6B upright microscope and a Leica DFC7000 T camera.
Aconitase in-gel assay
In-gel aconitase activities were measured as described previously (Holmes-Hampton et al., 2018; Tong and Rouault, 2006).
Aconitase activity gels are composed of a separating gel containing 8% acrylamide (132 mM Tris base, 132 mM borate, 3.6mM
citrate) and a 4% acrylamide (67 mM Tris base, 67 mM borate, 3.6 mM citrate) stacking gel. The running buffer contains 25 mM
Tris pH 8.3, 192 mM glycine, and 3.6 mM citrate. Protein concentration of macrophage lysates was measured by using the Pierce
BCA Protein Assay Kit and the sample buffer contained 25 mM Tris-Cl, pH 8.0, 10% glycerol, and 0.025% bromophenol blue.
Electrophoresis was carried out at 180 V, 4C, for 2 hours. Aconitase activities were assayed by incubating the gel in the dark at
37C in 100 mM Tris (pH 8.0), 1 mM NADP, 2.5 mM cis-aconitic acid, 5 mM MgCl2, 1.2 mM MTT, 0.3 mM phenazine methosulfate,
and 5 U/ml isocitrate dehydrogenase (Sigma).
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are presented as mean ± s.e.m. and analyzed using GraphPad Prism software (version 7.02; GraphPad). One-way ANOVA
(followed byDunnett’ or Tukey’smultiple comparison tests) and Student’s t test were performed unless otherwise stated. Differences
in percentage of fold change following ISCU siRNA knockdown were tested for significance using a one-sample-t test. In uniformly
labeled [U]-13C-glucose experiments, one-way ANOVA was applied to test for significance in glucose-derived isotopologues.
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